Feature

‘Immunotransplant’ shows potential for non-Hodgkin lymphoma

January 13, 2020
A combination of immunotherapy and stem cell transplantation could benefit patients with treatment-resistant non-Hodgkin lymphoma, according to…
Feature

Researchers uncover ‘novel drug target for glioblastoma’

January 10, 2020
An international study of glioblastoma revealed a cellular pathway that appears to contribute to glioma stem cell spread and proliferation. …
Point/Counter

Should gemcitabine plus nab-paclitaxel be used in the adjuvant pancreatic cancer setting?

HemOnc Today, January 10, 2020
The randomized phase 3 APACT trial was a well-designed adjuvant trial that evaluated the addition of nab-paclitaxel (Abraxane, Celgene) to…
Cover Story

Pancreatic cancer — a changing outlook if diagnosed early

HemOnc Today, January 10, 2020
Tumor DNA sequencing to identify appropriate targeted therapies is revolutionizing treatment of a variety of cancers, and pancreatic cancer — a…
Commentary

Provider education, practice champions can ensure successful integration of biosimilars into oncology care

January 6, 2020
By Kashyap Patel, MD Hundreds of millions of people worldwide rely on biologics to manage debilitating conditions and treat serious illnesses.
Feature

Study underway to evaluate novel T-cell therapy for hepatocellular carcinoma

January 3, 2020
An ongoing proof-of-concept clinical trial is underway to assess the use of a novel T-cell therapy for the treatment of advanced hepatocellular…
Feature

An emerging industry looks to take T cells to the cryobank

December 30, 2019
An increasing body of evidence shows that using younger, less heavily pretreated T cells results in more effective chimeric antigen receptor T-cell…
Point/Counter

Is it feasible to change the immunotherapy dose schedule for a patient in complete response?

HemOnc Today, December 25, 2019
POINT Immunotherapy represents a novel form of therapy in many ways, and it may not need to be given continuously. Currently approved checkpoint…
Cover Story

Cancer drug doses: More is not always better

HemOnc Today, December 25, 2019
Historically, the goal of cancer treatment has been to destroy as many cancer cells as possible through chemotherapy or radiation. Guided by this…
Point/Counter

Should screening of the gut microbiome be standard practice for patients with melanoma?

HemOnc Today, December 10, 2019
POINT We should screen the gut microbiome of our patients with melanoma. Currently, this practice is not necessary for treatment or clinical…